2023 World Conference on Lung Cancer (Posters)-P2.10. Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK

P2.10. Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK - PDF(Abstract)

Back to course

Pdf Summary

This study examined the costs of managing brain metastases (BM) in patients with anaplastic lymphoma kinase (ALK) advanced non-small-cell lung cancer (aNSCLC) who received first-line tyrosine kinase inhibitors (TKIs) in the UK. Previous publications have shown that patients with ALK aNSCLC and BM have a high economic burden compared to those without BM. Second- and third-generation ALK TKIs have been found to prevent or delay the occurrence of BM compared to the first-line TKI crizotinib, potentially reducing management costs. <br /><br />The study followed the methods used in previous publications that estimated the costs of managing ALK aNSCLC patients with and without BM in Spain and the US. The analysis was based on cost categories and resource use estimates in Spain, as they were more aligned with the UK healthcare system. Healthcare resources included medical visits, hospitalizations, laboratory tests, imaging, and surgical procedures. Diagnostic tests and treatment costs were excluded from the analysis. Unit costs were sourced from the National Health Service reference costs. The total annual cost of managing patients with each TKI was estimated using the 12-month and 24-month cumulative incidence of BM progression from clinical trials. <br /><br />The results showed that the management costs were higher for patients with BM compared to those without BM, with a cost difference of 8,838 per patient-year (PPY). This difference was primarily driven by the cost of radiotherapy or surgical resection, followed by medical visits. The study also found that lorlatinib and alectinib had lower management costs compared to crizotinib, based on the cumulative incidence of BM progression. <br /><br />In conclusion, this study demonstrated a direct relationship between the lower cumulative incidence of BM progression and lower cost burden in patients with ALK NSCLC receiving first-line TKIs in the UK. Additionally, lorlatinib had lower management costs compared to alectinib, potentially due to its lower incidence of BM progression.

Asset Subtitle

Hannah Le

Meta Tag

Speaker Hannah Le

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

brain metastases

anaplastic lymphoma kinase

advanced non-small-cell lung cancer

tyrosine kinase inhibitors

economic burden

ALK TKIs

crizotinib

costs of managing

management costs